Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MECPST-IPD

Financiado

Cerrado

Identification of inflammation pathways involved in the predisposition to decrea...

Identification of inflammation pathways involved in the predisposition to decreased neurogenesis and depression "Current drug therapies for depression have clinical benefits for many patients, however, there remains a large number of patients who either do not become entirely enabled or do not have any clinical benefits whatsoever. Depressi... ver más

30/04/2015

KINGS COLLEGE LOND...

222K€

Presupuesto del proyecto: 222K€

Líder del proyecto

KINGS COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-04-30 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

KINGS COLLEGE LONDON

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2015-67457-R CANNABIDIOL COMO ACELERADOR DE LA RESPUESTA FARMACOLOGICA AN... 194K€ Cerrado

PID2021-127497OB-I00 CARACTERIZACION DE UN MODELO ANIMAL DE DEPRESION INTEGRANDO... 206K€ Cerrado

PID2019-109033RB-I00 MECANISMOS DE ENTRADA A CEREBRO DE SEÑALES INFLAMATORIAS EN... 236K€ Cerrado

PID2020-113103RB-I00 MITOFAGIA, INMUNIDAD INNATA Y ESTRES OXIDATIVO EN LA ENFERME... 162K€ Cerrado

RTI2018-098264-B-I00 DESARROLLO TUMORAL, ESTRES SOCIAL CRONICO Y DEPRESION: DIFER... 67K€ Cerrado

INSPIRER A novel interdisciplinary framework to investigate neural an... 188K€ Cerrado

Líder del proyecto

KINGS COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 222K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "Current drug therapies for depression have clinical benefits for many patients, however, there remains a large number of patients who either do not become entirely enabled or do not have any clinical benefits whatsoever. Depression is estimated to cost society financially upward of 1% GDP, not to mention the toll on those suffering from depression including their families. During the past decades, enormous resources have been spent to find new mechanisms through which to treat the disease though without any results thus forcing researchers to change strategy. One development has been the general acceptance that depression may be composed of several pathologies rather than a single disease mechanism. In this project we incorporate three potential pathologies which have recently been associated with depression. The first is stress which is known as a common cause of depression followed by adult neurogenesis which has recently been suggested to regulate stress. Finally, inflammation has most recently been suggested to develop into a pathology which can cause depression. Our latest research has shown specifically an association between depressed individuals who are exposed to early life stress and inflammation and furthermore that these exposed individuals have an increased level of inflammation even in the absence of depression. We have therefore developed a hypothesis that individuals exposed to early life stress have an inflammatory predisposition and have a larger chance of developing depression if other pathologies (stress/decreased neurogenesis) are also present. If this hypothesis is validated, treatment methods targeting this predisposition will be of significant interest. To test this hypothesis we plan to develop an animal model which incorporates these pathologies which we can then further use to discover and thereafter test new treatment targets."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores